WILLIAM GILLESPIE: Open Payments
NPI 1538238118 · GLENDORA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,640 in 160 payments from 17 companies in 2025. Trend: 2023 $2,473 · 2024 $2,915 · 2025 $2,640
Food & beverage: $2,492Education: $148
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 20 | $437 |
| Teva Pharmaceuticals USA, Inc. | 23 | $429 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $309 |
| Janssen Pharmaceuticals, Inc | 15 | $247 |
| Otsuka America Pharmaceutical, Inc. | 19 | $244 |
| Neurocrine BioSciences, Inc. | 18 | $229 |
| E.R. Squibb & Sons, L.L.C. | 13 | $192 |
| Alkermes, Inc. | 17 | $166 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $144 |
| Bausch Health US, LLC | 3 | $57 |
Products named: HETLIOZ, CAPLYTA, REXULTI, UZEDY, INGREZZA, COBENFY, ARISTADA, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
